| BUDESONIDE + FORMOTEROL |
Bufomix Easyhaler® |
Orion Pharma (Aus) Pty Limited |
Asthma and chronic obstructive pulmonary disease (COPD) |
Nov 2023 |
Recommended |
| DOSTARLIMAB |
Jemperli® |
Glaxosmithkline Australia Pty Ltd |
Endometrial cancer |
Nov 2023 |
Recommended |
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative
(HER2-) breast cancer |
Nov 2023 |
Recommended |
| CHLORMETHINE HYDROCHLORIDE |
Ledaga® |
Juniper Biologics Pty Ltd |
Mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) |
Nov 2023 |
Recommended |
| TERIPARATIDE |
Terrosa® |
Gedeon Richter Australia Pty Ltd |
Osteoporosis |
Nov 2023 |
Recommended |
| OXYBUTYNIN |
Oxytrol® |
Theramex Australia Pty Ltd |
Detrusor overactivity in patients unable to tolerate or unable to swallow oral oxybutynin |
Nov 2023 |
Advice Provided |
| OLAPARIB |
Lynparza® |
Astrazeneca Pty Ltd |
Metastatic castration-resistant prostate cancer (mCRPC) |
Nov 2023 |
Not Recommended |
| MARIBAVIR |
Livtencity® |
Takeda Pharmaceuticals Australia Pty Ltd |
Post-transplant cytomegalovirus (CMV) |
Nov 2023 |
Not Recommended |
| RISANKIZUMAB |
Skyrizi® |
Abbvie Pty Ltd |
Chronic plaque psoriasis (CPP) |
Nov 2023 |
Recommended |
| MIDAZOLAM |
Zyamis® |
Clinect Pty Ltd |
Generalised convulsive status epilepticus (GCSE) |
Nov 2023 |
Recommended |
| EMPAGLIFLOZIN |
Jardiance® |
Boehringer Ingelheim Pty Ltd |
Chronic kidney disease |
Nov 2023 |
Recommended |
| IVACAFTOR |
Kalydeco® |
Vertex Pharmaceuticals (Australia) Pty. Ltd. |
Cystic fibrosis (CF) with the CF transmembrane conductance regulator (CFTR) gene mutation |
Nov 2023 |
Recommended |
| NIRMATRELVIR AND RITONAVIR |
Paxlovid® |
Pfizer Australia Pty Ltd |
SARS-CoV-2 infection |
Nov 2023 |
Advice Provided |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Squamous cell carcinoma (SCC) |
Nov 2023 |
Recommended |
| MEDROXYPROGESTERONE ACETATE |
Depo-Provera® |
Pfizer Australia Pty Ltd |
Unrestricted benefit |
Nov 2023 |
Recommended |
| FLUTICASONE PROPIONATE + SALMETEROL |
Salflumix Easyhaler® |
Orion Pharma (Aus) Pty Limited |
Asthma and chronic obstructive pulmonary disease (COPD) |
Nov 2023 |
Recommended |
| CEMIPLIMAB |
Libtayo® |
Sanofi-Aventis Australia Pty Ltd |
Non small cell lung cancer (NSCLC) |
Nov 2023 |
Recommended |
| ELTROMBOPAG |
Revolade® |
Novartis Pharmaceuticals Australia Pty Limited; Haematology Society Of Australia And
New Zealand |
Aplastic anaemia (AA) |
Nov 2023 |
Recommended |
| EDARAVONE |
Radicava® |
Teva Pharma Australia Pty Ltd |
Amyotrophic lateral sclerosis (ALS) |
Nov 2023 |
Not Recommended |
| CABOZANTINIB |
Cabometyx® |
Ipsen Pty Ltd |
Differentiated thyroid cancer (DTC) |
Nov 2023 |
Not Recommended |
| ADALIMUMAB |
Hadlima® |
Organon Pharma Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Nov 2023 |
Recommended |
| TERIPARATIDE |
Teriparatide Lupin |
Generic Health Pty Ltd |
Osteoporosis |
Nov 2023 |
Recommended |
| OSIMERTINIB |
Tagrisso® |
Astrazeneca Pty Ltd |
Non small cell lung cancer (NSCLC) |
Nov 2023 |
Recommended |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
Astrazeneca Pty Ltd |
Human epidermal growth factor receptor 2 (HER2)-low breast cancer |
Nov 2023 |
Not Recommended |
| LENALIDOMIDE |
Lenalide® |
Juno Pharmaceuticals Pty Ltd |
Multiple myeloma (MM) Myelodysplastic syndromes (MDS) Mantle cell lymphoma (MCL) |
Nov 2023 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Muscle invasive urothelial carcinoma (MIUC) |
Nov 2023 |
Deferred |
| ICOSAPENT ETHYL |
Vazkepa® |
Seqirus (Australia) Pty Ltd |
Atherosclerotic cardiovascular disease with elevated triglycerides |
Nov 2023 |
Not Recommended |
| SEMAGLUTIDE |
Wegovy® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Severe obesity |
Nov 2023 |
Not Recommended |
| OLAPARIB |
Lynparza® |
Astrazeneca Pty Ltd |
Human epidermal growth factor receptor 2 (HER2)-negative early breast cancer |
Nov 2023 |
Recommended |
| LENACAPAVIR |
Sunlenca® |
Gilead Sciences Pty Limited |
Human immunodeficiency virus (HIV) |
Nov 2023 |
Recommended |
| TISLELIZUMAB |
Tevimbra® |
Beigene Aus Pty Ltd |
Non small cell lung cancer (NSCLC) |
Nov 2023 |
Not Applicable |
| APREMILAST |
Otezla® |
Amgen Australia Pty Limited |
Chronic plaque psoriasis (CPP) |
Nov 2023 |
Recommended |
| DIFELIKEFALIN |
Korsuva® |
Vifor Pharma Pty Limited |
Chronic kidney disease associated pruritus |
Nov 2023 |
Recommended |
| CLADRIBINE |
Mavenclad® |
Merck Healthcare Pty Ltd |
Relapsing-remitting multiple sclerosis (RRMS) |
Nov 2023 |
Not Recommended |
| SECUKINUMAB |
Cosentyx® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Hidradenitis suppurativa (HS) |
Nov 2023 |
Recommended |
| MAVACAMTEN |
Camzyos® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Hypertrophic cardiomyopathy |
Nov 2023 |
Recommended |
| SACITUZUMAB GOVITECAN |
Trodelvy® |
GILEAD SCIENCES PTY LIMITED |
Hormone receptor-positive (HR+) human epidermal growth factor receptor-2 negative
(HER2-) advanced or metastatic breast cancer |
Nov 2023 |
Not Recommended |
| DAUNORUBICIN WITH CYTARABINE |
Vyxeos® |
Jazz Pharmaceuticals ANZ Pty Ltd |
Acute myeloid leukaemia |
Nov 2023 |
Recommended |
| MOLNUPIRAVIR |
Lagevrio® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Mild to moderate COVID-19 |
Nov 2023 |
Advice Provided |
| DUPILUMAB; UPADACITINIB (REVIEW OF COST-EFFECTIVENESS OF DRUGS FOR ATOPIC DERMATITIS) |
|
Sanofi-Aventis Australia Pty Ltd; AbbVie Pty Ltd |
Severe atopic dermatitis |
Nov 2023 |
Advice Provided |